Clinical findings in individuals who were diagnosed with mpox after having received the first dose of MVA
| n (%) | |
| Median days between MVA-BN and symptom onset (IQR) | 4 (3–9) |
| Median days between symptom onset and last sexual encounter (IQR) | 4 (3–6) |
| Sex partners in the 3 months prempox testing | |
| 1 | 1/13 (8) |
| 7 | 9/13 (69) |
| >6 | 3/13 (23) |
| Systemic symptoms | 11/15 (73) |
| No prodromal symptoms | 6/15 (40) |
| Fatigue/lethargy | 9/15 (60) |
| Fever/chills | 8/15 (53) |
| Myalgia | 4/15 (27) |
| Sore throat | 4/15 (27) |
| Localised symptoms | 15/15 (100) |
| Number of skin lesions at peak | |
| 1–10 | 11/15 (73) |
| 11–25 | 1/15 (7) |
| 26–99 | 2/15 (13) |
| >100 | 1/15 (7) |
| Skin lesions distribution | |
| Genital (penis and/or pubic and/or scrotal) | 6/15 (40) |
| Anal | 9/15 (60) |
| Face/scalp | 6/15 (40) |
| Torso | 6/15 (40) |
| Limbs | 10/15 (67) |
| ≥3 anatomical sites involved | 8/15 (53) |
| Mucosal involvement (oral and/or rectal) | 4/15 (27) |
| Lymphadenopathy | 9/15 (60) |
| Sexual health coinfections | 5/15 (33) |
| HSV PCR test positive | 0/11 (0) |
| Syphilis PCR test positive | 0/9 (0) |
| Chlamydia trachomatis NAAT test positive | 5/15 (33) |
| Neisseria gonorrhoeae NAAT test positive | 1/15 (7) |
HSV, herpes simplex virus; mpox, monkeypox; MVA-BN, single dose of modified vaccinia Ankara; NAAT, Nucleic Acid Amplification Test.